Business Insider reports that Robert F. Kennedy Jr.'s Department of Health and Human Services said it would not pursue pharmacies that compound and sell BPC-157 to patients, provided they meet certain conditions. Five other peptides popular in the gym world got the same treatment, which the piece describes as having huge fans and dubious evidence behind them.

BPC is short for "body protection compound," a peptide first isolated from human gastric juice in the 1990s by Croatian scientist Predrag Sikiric. It is one half of the so-called "Wolverine shot," a stack with TB-500 promoted on social media as a shortcut to repairing damaged tendons and ligaments.

What the policy does not do

The enforcement decision does not make BPC-157 FDA-approved, and Business Insider is blunt that the fundamental questions about safety and effectiveness remain unanswered. What it may do is move some users away from unregulated online sellers and toward a clinician-mediated prescription, which is a sourcing fix rather than an evidence fix.

One trial, 20 patients

A first-of-its-kind clinical trial scheduled for summer 2027 will follow 20 patients after shoulder surgery to test whether BPC speeds healing and whether side effects appear. It is randomized, double-blind and placebo-controlled, comparing blood-test and MRI data against measures of pain and function.

Principal investigator Dr. Shiloah Kviatkovsky, of the University of Arkansas for Medical Sciences, told Business Insider the trial is an early step toward assessing whether the compound is safe and effective for human use. "The market is ahead of the research, which is a little frightening," she said.

The contamination problem

Animal studies cited in the piece suggest the peptide may accelerate tissue repair and can be tolerated at high doses. Human evidence remains scant, and doctors have raised a theoretical concern that its blood-vessel-promoting effect could fuel tumors, though no research has found a link between BPC and cancer in practice.

The sharper near-term risk is what is actually in the vial. Gray-market product can be contaminated, inconsistently dosed or counterfeit, and one seller interviewed described his wife developing fever, chills and diarrhea consistent with endotoxin exposure.

Bottom line

A peptide sold in a Brooklyn bodega now has federal enforcement cover and no completed human trial behind it. That gap closes, if it closes, in 2027.